Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

Stroke & Heart Attack
AHA: Stroke or Stroke Plus Carotid or Vertebral Artery Dissection Almost Doubled Risk of Heart Attack Within One Year
02/01/2024

American Heart Association News

American Heart Association News ...
Heart attack risk almost doubles in the first year after a stroke or when combined with a tear in a neck artery wall; however, a tear without a stroke does not seem to raise heart attack risk, according to preliminary research.
Heart attack risk almost doubles in the first year after a stroke or when combined with a tear in a neck artery wall; however, a tear without a stroke does not seem to raise heart attack risk, according to preliminary research.
Heart attack risk almost doubles...
02/01/2024
Cath Lab Digest
Hearing Loss Prevention Could Delay, Prevent Dementia Onset
News
Hearing Loss Prevention Could Delay, Prevent Dementia Onset
01/29/2024
Hearing aids could delay or prevent dementia onset, according to a population-based cohort study recently published in the journal JAMA Otolaryngology Head & Neck Surgery.
Hearing aids could delay or prevent dementia onset, according to a population-based cohort study recently published in the journal JAMA Otolaryngology Head & Neck Surgery.
Hearing aids could delay or...
01/29/2024
Psych Congress Network

Advertisement

a doctor holds a generic orange pill bottle
News
Zenzedi CII 30 mg Tablets Recalled Over Mislabeling Concerns
01/29/2024
zurity Pharmaceuticals, Inc. has issued a voluntary recall of 1 lot of Zenzedi CII 30 mg tablets after a Nebraska pharmacist discovered carbinoxamine maleate, an antihistamine, in a bottle labeled as Zenzedi 30 mg.
zurity Pharmaceuticals, Inc. has issued a voluntary recall of 1 lot of Zenzedi CII 30 mg tablets after a Nebraska pharmacist discovered carbinoxamine maleate, an antihistamine, in a bottle labeled as Zenzedi 30 mg.
zurity Pharmaceuticals, Inc. has...
01/29/2024
Neurology
Secondhand Smoke Exposure Significantly Associated With Headache, Migraines
News
Secondhand Smoke Exposure Significantly Associated With Headache, Migraines
01/25/2024
Heavy secondhand smoke (SHS) exposure could increase risk of severe headaches or migraines in people who have never smoked, according to a cross-sectional study published in the journal Headache. 
Heavy secondhand smoke (SHS) exposure could increase risk of severe headaches or migraines in people who have never smoked, according to a cross-sectional study published in the journal Headache. 
Heavy secondhand smoke (SHS)...
01/25/2024
Neurology
News
Study Explores Use of DBS to Treat Severe Opioid Use Disorder
01/23/2024

Tom Valentino

Tom Valentino
Allegheny Health Network seeks 2 additional patients for a trial in which patients with treatment-resistant opioid use disorder receive continuous electrical pulses to the brain’s addiction and reward center to curb severe cravings.
Allegheny Health Network seeks 2 additional patients for a trial in which patients with treatment-resistant opioid use disorder receive continuous electrical pulses to the brain’s addiction and reward center to curb severe cravings.
Allegheny Health Network seeks 2...
01/23/2024
Addiction Professional

Advertisement

An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
Gray Matter Reduced in Patients With Early-Onset Psychosis
01/23/2024
Patients with early-onset psychosis had significantly lower volume of gray matter in their brains compared with healthy control subjects, according to study findings published in Molecular Psychiatry.
Patients with early-onset psychosis had significantly lower volume of gray matter in their brains compared with healthy control subjects, according to study findings published in Molecular Psychiatry.
Patients with early-onset...
01/23/2024
Psych Congress Network
neurologist and patient
News
FDA Approves Rechargeable Neurostimulator to Treat Movement Disorders
01/23/2024
The FDA approved a rechargeable neurostimulator that features a sensing-enabled DBS system for personalized treatment of movement disorders such as Parkinson disease, essential tremor, dystonia, and epilepsy.
The FDA approved a rechargeable neurostimulator that features a sensing-enabled DBS system for personalized treatment of movement disorders such as Parkinson disease, essential tremor, dystonia, and epilepsy.
The FDA approved a rechargeable...
01/23/2024
Neurology
brain waves
News
Targeted Brain Stimulation Could Benefit Chronic Pain Treatment
01/22/2024
Less than 2 minutes of transcranial magnetic stimulation that targeted the left dorsolateral prefrontal cortex (DLPFC) of the brain boosted hypnotizability for about an hour in low-to-medium hypnotizable people living with fibromyalgia.
Less than 2 minutes of transcranial magnetic stimulation that targeted the left dorsolateral prefrontal cortex (DLPFC) of the brain boosted hypnotizability for about an hour in low-to-medium hypnotizable people living with fibromyalgia.
Less than 2 minutes of...
01/22/2024
Neurology

Advertisement

News
Seizure Med Under Class I Recall
01/17/2024
A Class I recall has been issued for a single lot of the anticonvulsant vigabatrin for oral solution because of a potential for powder to leak from product pouches and subsequent underdosing, according to the January 17, 2024, US Food and...
A Class I recall has been issued for a single lot of the anticonvulsant vigabatrin for oral solution because of a potential for powder to leak from product pouches and subsequent underdosing, according to the January 17, 2024, US Food and...
A Class I recall has been issued...
01/17/2024
Pharmacy Learning Network
Pet Ownership Could Slow Cognitive Decline in Older Adults Living Alone
News
Pet Ownership Could Slow Cognitive Decline in Older Adults Living Alone
01/16/2024
Owning a pet could help to slow verbal memory, verbal fluency, and composite verbal cognition decline in older adults living on their own, according to recent prospective cohort study results published in JAMA Network Open. 
Owning a pet could help to slow verbal memory, verbal fluency, and composite verbal cognition decline in older adults living on their own, according to recent prospective cohort study results published in JAMA Network Open. 
Owning a pet could help to slow...
01/16/2024
Neurology

Advertisement

Advertisement

News

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use